圣因生物宣布与基因泰克达成RNAi药物研发战略合作

Group 1 - The core point of the article is that Saintgen Biotech has entered into a global research and licensing agreement with Genentech to develop an RNA interference (RNAi) therapy [1] - Under the agreement, Saintgen Biotech will grant Genentech exclusive global rights for the development and commercialization of the RNAi drug, while Saintgen will handle early-stage research [1] - Genentech will be responsible for all subsequent clinical development and commercialization activities of the drug [1] Group 2 - Saintgen Biotech's proprietary RNAi drug development platform includes novel drug chemical modifications and delivery technologies, which can be utilized to develop potential breakthrough siRNA drugs across multiple disease areas [1] - According to the agreement terms, Saintgen Biotech will receive an upfront payment of $200 million, with the potential to earn up to $1.5 billion in development and sales milestone payments, along with tiered royalties [1]